• Sofinnova, LSP lead $17M round for gene therapy player XyloCor fiercebiotech
    December 29, 2018
    XyloCor Therapeutics raised $17 million in its series A round to advance a gene therapy pipeline for cardiovascular disease. Its lead asset is a treatment for angina that is poised to enter the clinic in 2019....
PharmaSources Customer Service